Research & Development

Abliva’s in-house R&D capabilities have been instrumental in creating and delivering a portfolio that includes several projects with mechanisms of action suitable for a wide range of primary mitochondrial diseases

Our portfolio

KL1333: Innovative therapy in late-stage development

Project status: Dosing in patients is ongoing in the FALCON study

In June 2023, the first patient was dosed in Wave 1 of the FALCON study with KL1333, and by December all patients in the first wave of the study had been recruited. An interim analysis will take place after all Wave 1 patients have been treated for 24 weeks. The analysis will include a futility analysis (a non-futile study is a positive result) as well as a final sample size evaluation for Wave 2 of the study. KL1333 has Orphan Drug Designation (ODD) in both Europe and the U.S. as well as Fast Track designation in the U.S.

Mitochondrial disease target population: MELAS-MIDD, KSS-CPEO and MERRF

Abliva’s lead candidate, KL1333, has been designed to treat chronic fatigue and myopathy (muscle weakness) in genetically confirmed adult patients with primary mitochondrial disease. Diagnoses can include MELAS-MIDD and KSS-CPEO spectrum disorders as well as MERRF syndrome. The drug candidate is intended for long-term oral treatment.

Mechanism of action: NAD⁺/NADH modulation

KL1333 is a potent modulator of the cellular levels of NAD⁺ and NADH, central co-enzymes in the cell’s energy metabolism. This modulation leads to the formation of new mitochondria and improved energy levels at the cellular level which is expected to translate into a system-wide improvement in energy and organ function of patients in the FALCON study.

NV354: First-in-class therapeutic targeting high unmet need

Project status: Preclinical development completed

The program has completed preclinical development and has been granted Orphan (Drug) Designation both in the EU and the U.S. Given the prioritization of KL1333, no significant cost-intensive operational activities are planned for NV354 at this time.

Mitochondrial disease target population: Neurology

NV354 is being developed for mitochondrial disease with neurologic complications, in particular at insufficient activity in the mitochondrial protein complex I. The resulting deficiency in energy conversion contributes to clinical signs and symptoms in many types of mitochondrial disease, including neurologic complications seen in Leigh syndrome, MELAS, or LHON. There are also additional expansion opportunities outside of mitochondrial disease, including neurologic conditions where mitochondrial dysfunction has been confirmed.

The drug candidate was discovered due to its ability to increase mitochondrial function in cells from mitochondrial Leigh syndrome patients. Leigh syndrome usually debuts at one to two years of age and includes psychomotor regression, hypotonia and developmental delays. The disease is fatal, and children with early-onset Leigh syndrome usually die before adulthood.

Mechanism of action: Energy replacement

Brain-penetrable NV354 is based on an innovation in which the body’s own energy substrate, succinate, is made available in the cell via a prodrug technology. A prodrug is an inactive drug that is activated first when it enters the body by the transformation of its chemical structure.

Early programs

Abliva has efforts ongoing to identify additional portfolio opportunities focused on the regulation and stabilization of cellular energy production.